• Home
  • Agric
  • Sci & Tech
  • Health
  • Environment
  • Hausa News
  • More
    • Business/Banking & Finance
    • POLITICS
    • Entertainments & Sports
    • International
    • Investigation
    • Law & Human Rights
    • Africa
    • ACCOUNTABILITY/CORRUPTION
    • Hassan Gimba
    • Column
    • Prof. Jibrin Ibrahim
    • Prof. M.K. Othman
    • Defense/Security
    • Education
    • Energy/Electricity
    • Entertainment/Arts & Sports
    • Society and Lifestyle
    • Food & Agriculture
    • Health & Healthy Living
    • International News
    • Interviews
    • Investigation/Fact-Check
    • LAW & HUMAN RIGHTS
    • Oil & Gas/Mineral Resources
    • PRESS FREEDOM/JOURNALISM/PR
    • General News
    • Presidency
  • About Us
    • Contact Us
    • Board Of Advisory
    • Privacy Policy
    • Ethics Policy
    • Teamwork And Collaboration Policy
    • Fact-Checking Policy
    • Advertising
  • Media OutReach Newswire
    • Wire News
  • The Stories
Facebook Twitter Instagram
Trending
  • Land loss, ageing farmers put smallholders at risk
  • Africa pushes for climate finance, adaptation action ahead of COP32
  • Media credibility crucial to success of 2027 polls – GOCOP president
  • NEMA distributes relief materials to Abia windstorm, erosion victims
  • Radda flags off ₦1.4bn Ingawa hospital upgrade
  • LAWMA targets faster waste removal in 60-day plan
  • NAFDAC seizes, destroys ₦100bn worth of unsafe products
  • Jigawa confirms 242 diphtheria cases across 19 LGAs
Facebook Twitter Instagram YouTube
AsheNewsAsheNews
  • Home
  • Agric

    Land loss, ageing farmers put smallholders at risk

    November 22, 2026

    Nigeria’s coffee growers face an uphill road to recognition

    November 21, 2026

    Ogun farmers call for better roads, security, inputs

    November 20, 2026

    Kaduna poultry farmers struggle with feed costs

    November 20, 2026

    Enugu residents call for steps to stabilise onion prices

    November 20, 2026
  • Sci & Tech

    Foreign AI Chatbots could expose patients’ medical data

    November 21, 2026

    GTA VI claims biggest launch in entertainment history

    November 21, 2026

    Expert calls for wider access to digital services in Nigeria

    November 20, 2026

    Rural connectivity key to inclusive digital growth, expert says

    November 20, 2026

    IAR, NBMA train stakeholders on managing low-level presence of GM crops

    November 20, 2026
  • Health

    Radda flags off ₦1.4bn Ingawa hospital upgrade

    November 21, 2026

    LAWMA targets faster waste removal in 60-day plan

    November 21, 2026

    NAFDAC seizes, destroys ₦100bn worth of unsafe products

    November 21, 2026

    Jigawa confirms 242 diphtheria cases across 19 LGAs

    November 21, 2026

    Rotary takes free cancer screening to Plateau community

    November 21, 2026
  • Environment

    Africa pushes for climate finance, adaptation action ahead of COP32

    November 21, 2026

    NEMA distributes relief materials to Abia windstorm, erosion victims

    November 21, 2026

    Bayelsa boat accident renews concerns over waterway safety

    November 21, 2026

    Ghana warns of El Niño-linked health risks as harmattan intensifies

    November 20, 2026

    Ghana’s UCC Vice-Chancellor meets 12-year-old student, urges focus on excellence

    November 20, 2026
  • Hausa News

    Foundation unveils public sector reform playbook

    November 12, 2026

    Tinubu asks Reps to approve N10.79tn external borrowing for 2026 budget

    November 11, 2026

    UNA signs MoU to launch air Bissau in Guinea-Bissau

    June 15, 2026

    Otti plans 250-room 5-star hotel in Umuahia

    April 11, 2026

    Anti-quackery task force seals 4 fake hospitals in Rivers

    August 29, 2025
  • More
    1. Business/Banking & Finance
    2. POLITICS
    3. Entertainments & Sports
    4. International
    5. Investigation
    6. Law & Human Rights
    7. Africa
    8. ACCOUNTABILITY/CORRUPTION
    9. Hassan Gimba
    10. Column
    11. Prof. Jibrin Ibrahim
    12. Prof. M.K. Othman
    13. Defense/Security
    14. Education
    15. Energy/Electricity
    16. Entertainment/Arts & Sports
    17. Society and Lifestyle
    18. Food & Agriculture
    19. Health & Healthy Living
    20. International News
    21. Interviews
    22. Investigation/Fact-Check
    23. LAW & HUMAN RIGHTS
    24. Oil & Gas/Mineral Resources
    25. PRESS FREEDOM/JOURNALISM/PR
    26. General News
    27. Presidency
    Featured
    Recent

    Land loss, ageing farmers put smallholders at risk

    November 22, 2026

    Africa pushes for climate finance, adaptation action ahead of COP32

    November 21, 2026

    Media credibility crucial to success of 2027 polls – GOCOP president

    November 21, 2026
  • About Us
    1. Contact Us
    2. Board Of Advisory
    3. Privacy Policy
    4. Ethics Policy
    5. Teamwork And Collaboration Policy
    6. Fact-Checking Policy
    7. Advertising
    Featured
    Recent

    Land loss, ageing farmers put smallholders at risk

    November 22, 2026

    Africa pushes for climate finance, adaptation action ahead of COP32

    November 21, 2026

    Media credibility crucial to success of 2027 polls – GOCOP president

    November 21, 2026
  • Media OutReach Newswire
    • Wire News
  • The Stories
AsheNewsAsheNews
Home»Health & Healthy Living»Mpox, cholera outbreaks underscore importance of Gavi’s African Vaccine Initiative – But can it ensure equity?
Health & Healthy Living

Mpox, cholera outbreaks underscore importance of Gavi’s African Vaccine Initiative – But can it ensure equity?

EditorBy EditorSeptember 10, 2024Updated:September 10, 2024No Comments7 Mins Read
A child received an oral cholera vaccine, one of the vaccines prioritised by AVMA.
Share
Facebook Twitter LinkedIn Pinterest Email

While COVID exposed the urgency of ensuring that Africa, through Gavi’s African Vaccine Initiative, can manufacture vaccines, the current mpox and cholera outbreaks have painfully underscored the continent’s vulnerability.

By Kerry Cullinan

African countries affected by mpox are dependent on vaccine donations from wealthy countries, while a dire global shortage of cholera vaccines has forced the World Health Organization (WHO) to advise countries to give people one dose instead of the optimal two.

Back in June, the vaccine platform, Gavi, launched the African Vaccine Manufacturing Accelerator (AVMA), together with the African Union and Africa Centres for Disease Control and Prevention (Africa CDC).

“AVMA is a financing mechanism established to make up to $1.2 billion available over 10 years, commencing with AVMA’s launch in June 2024, to accelerate the expansion of commercially viable vaccine manufacturing in Africa,” a Gavi spokesperson told Health Policy Watch.

High hopes are invested in AVMA, but the initiative has also been criticised for offering incentives that favour established international manufacturers rather nurturing than smaller, truly African manufacturers.

Initiative ‘favours major producers’

ALSO READ Mpox: AIDS Foundation advocates for vaccine access, public health over profits

“Without proper attention to who owns and controls the production and underlying technologies, there is a risk that well-meaning donor investments reinforce market dynamics that favour a handful of major international producers over truly local efforts. This is particularly relevant for AVMA,” argue researchers Els Torreele and Heather Sherwin in the journal, PLOS.

Gavi defines local production as “geographically located on the African continent”, which means that international non-African companies are eligible for financing. 

“We have clearly stated throughout extensive consultations, as well as in public board documents, that eligibility for AVMA is based on geographic location of manufacturing rather than location of ownership,” Gavi’s spokesperson told Health Policy Watch.

Gavi wants to build “a thriving and sustainable vaccine manufacturing sector on the African continent” and is “dedicated to fostering a sustainable and resilient manufacturing base in Africa”.

“With that objective in mind, any manufacturing operations physically located in Africa which serves that end, irrespective of ownership, will be eligible,” added the spokesperson.

‘Not building equitable access’

But Torreele, in an earlier article, argues that this will not build equitable access.

“To ensure equitable vaccine access in low and middle-income countries when and where needed, countries and local producers in the Global South must have ownership and decision-making over vaccine manufacturing technology and facilities, what they produce, and for whom,” she says.

“Moderna or BioNTech producing their proprietary vaccines in Africa does not build sustained regional capacity or resilience to respond to local health needs. Instead, it risks deepening dependencies on commercial interests that will always be prioritised over people’s health needs in shareholder-driven companies.”

But Gavi believes that its recipe of international and local players offers the best remedy for the dearth of African manufacturers.

“Developing a substantial and durable vaccine manufacturing industry in Africa, starting from a small base, needs local and regional entrepreneurs, and international resources and capacity,” says the spokesperson.

“The AVMA’s structure, with caps on the total amount of support individual manufacturers can receive and inclusion of African and international owners, is designed to attract support and investment from the broadest possible constituency,” it argues.

“This will allow the continent to benefit from a broad ecosystem of actors if long-term capacity is to be established from a relatively low baseline. This will also incentivize investment and ensure critical skills and capacity are transferred to the African continent.”

High bar for AVMA support

 AVMA offers subsidies at two critical points: when a company is awarded World Health Organization (WHO)  pre-qualification for “priority vaccines”; and per-dose on delivery if they are successful in securing Gavi-UNICEF vaccine tenders. 

Critics say this bar is too high, as WHO pre-qualification favours large international companies with access to capital to finance product development and a regulatory dossier, rather than local players.

“While we would wish that African manufacturing gains momentum and builds scale as soon as possible safety, standards and quality assurance are vital elements,” Gavi responds.

“Adherence to correct regulatory processes is absolutely essential, hence the WHO pre-qualification requirement.”

The spokesperson also called for national, regional and global actors to build “the right regulatory environment” for “sustainable vaccine manufacturing on the continent”.

A critical component of this is the African Medicines Agency (AMA), which is limping along without ratification from many of the continent’s powerhouse countries. It would enable continental approval of medicines instead of all 55 different countries having their own approval processes, which are painfully slow.

One of the hitches with mpox vaccine donations has been the slow pace of countries to grant regulatory approval for them. The Democratic Republic of Congo, which has been battling large mpox outbreaks for two years, only approved the vaccine in late June.

Vaccine accelerator’s focus

AVMA’s payments to manufacturers are incentive-based, with the highest – called “milestone payments” – being offered to “modes of manufacturing most likely to support pandemic preparedness.” 

“Accelerator payments” are also being offered, which are a per-dose top-up in addition to the market rate that manufacturers are paid on winning Gavi-UNICEF tenders. These payments acknowledge the cost and risk of vaccine development and production.

AVMA will support mRNA and viral vector platforms covering eight key vaccines for cholera, malaria,  measles-rubella (MR), hexavalent (wP), Yellow Fever, pneumococcal, Ebola,  Rotavirus as well as the six -in-one hexavalent vaccine (protecting against diphtheria, tetanus, whooping cough, poliomyelitis, Haemophilus influenza type B and hepatitis B).

“The idea is to focus manufacturers on production in the most viable markets, or priority antigens, helping to secure accelerated, competitive entry of new manufacturers where there is an unmet market need,” said the spokesperson.

Support will be “predominantly directed towards vaccines whose drug substance is manufactured in Africa, with initial consideration also given for ‘fill & finish only’ projects using imported drug substance.”

Business-as-usual ‘will not deliver equity’

But Torreele is sceptical: “Many of the investments in local vaccine manufacturing, even with public funds, seem to assume that new producers will be able to successfully compete and be profitable in the global vaccine market. 

She describes the vaccine market as ”cut-throat and oligopolistic”, with “significant entry barriers, and favouring the biggest players adopting economies-of-scale business models”. 

“In 2021, excluding COVID-19 vaccines, just four pharmaceutical corporations (MSD, GSK, Sanofi and Pfizer) captured 73% of the global vaccine market worth $42 billion, while the single biggest producer by volume, the Serum Institute of India, barely captured 2% of the value while supplying 20% of all doses at near-cost prices,” she notes.

Torreele and Sherwin urge AVMA and the European Union’s Global Gateway African investment initiative to “target the needs of emerging local producers”, including “access to affordable capital to finance at-risk the technical work needed to adapt, optimize, and establish a regulatory dossier for submission to regulatory authorities and other push incentives.” 

“Business-as-usual market dynamics will not deliver equity,” they argue.

What about the Pandemic Agreement?

Meanwhile, during the resumed pandemic agreement negotiations in Geneva on Monday, the South Centre said: “Current efforts for equitable and timely access to vaccines, treatments and diagnostics (VTD) are ad hoc, voluntary, uncoordinated, underfunded and focused on last-mile delivery.”

The South Centre, which represents 55 organisations in the Global South and is a stakeholder in the negotiations, called for the core provisions of the pandemic agreement to  “provide for concrete means to enhance equity and development allocation and procurement of these VDTs”.

A robust pandemic agreement, together with AVMA and other initiatives may finally change Africa’s vaccine desert – but these efforts need political will, innovative thinking and financial resources.

HealthPolicyWatch

Africa CDC African Medicines Agency AVMA BioNTech GAVI GSK MSD Pfizer Sanofi UNICEF WHO
Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Editor
  • Website

Related Posts

Radda flags off ₦1.4bn Ingawa hospital upgrade

November 21, 2026

LAWMA targets faster waste removal in 60-day plan

November 21, 2026

NAFDAC seizes, destroys ₦100bn worth of unsafe products

November 21, 2026

Leave A Reply Cancel Reply

Land loss, ageing farmers put smallholders at risk

November 22, 2026

Africa pushes for climate finance, adaptation action ahead of COP32

November 21, 2026

Media credibility crucial to success of 2027 polls – GOCOP president

November 21, 2026

NEMA distributes relief materials to Abia windstorm, erosion victims

November 21, 2026
About Us
About Us

ASHENEWS (AsheNewsDaily.com), published by PenPlus Online Media Publishers, is an independent online newspaper. We report development news, especially on Agriculture, Science, Health and Environment as they affect the under-reported rural and urban poor.

We also conduct investigations, especially in the areas of ASHE, as well as other general interests, including corruption, human rights, illicit financial flows, and politics.

Contact Info:
  • 1st floor, Dogon Daji House, No. 5, Maiduguri Road, Sokoto
  • +234(0)7031140009
  • ashenewsdaily@gmail.com
Facebook Twitter Instagram Pinterest
© 2026 All Rights Reserved. ASHENEWS Daily Designed & Managed By DeedsTech

Type above and press Enter to search. Press Esc to cancel.